Back

Zasocitinib shows superior efficacy to deucravacitinib in Phase 3 comparison

Verifying
  • Zasocitinib outperformed deucravacitinib in new Phase 3 head-to-head results.
  • Zasocitinib was evaluated as a convenient once-daily pill for skin clearance.
  • The results reinforced zasocitinib's potential for rapid and durable skin clearance.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.